BR0308556A - Tecnologia de otimização do segmento de sistema de serotonina e de catecolaminas - Google Patents

Tecnologia de otimização do segmento de sistema de serotonina e de catecolaminas

Info

Publication number
BR0308556A
BR0308556A BR0308556-2A BR0308556A BR0308556A BR 0308556 A BR0308556 A BR 0308556A BR 0308556 A BR0308556 A BR 0308556A BR 0308556 A BR0308556 A BR 0308556A
Authority
BR
Brazil
Prior art keywords
precursor
serotonin
amino acid
catecholamine
optimization technology
Prior art date
Application number
BR0308556-2A
Other languages
English (en)
Inventor
Martin C Hinnz
Original Assignee
Martin C Hinnz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Martin C Hinnz filed Critical Martin C Hinnz
Publication of BR0308556A publication Critical patent/BR0308556A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"TECNOLOGIA DE OTIMIZAçãO DO SEGMENTO DE SISTEMA DE SEROTONINA E DE CATECOLAMINAS". Um processo de tratamento de disfunção de neurotransmissores em um paciente. O processo inclui a etapa de se administrar um aminoácido precursor de uma catecolamina numa faixa terapêutica balanceada e eficaz. O precursor de catecolamina é, de preferência, L-dopa, mas pode ser alternativamente tirosina, D,L-Fenilalanina, ou um isómero ativo seu, e N-acetil-L-tirosina, ou outro precursor aminoácido de L-dopa. é também administrado um aminoácido precursor de serotonina numa faixa terapêutica eficaz. O precursor de serotonina é de preferência 5-HTP, mas pode ser alternativamente triptofano. é administrado, de preferência, pelo menos um co-fator. As opções de co-fatores incluem Vitamina B6, Vitamina C, Cálcio, Foliato e Cisteína. é também descrito um processo de administração e verificação periódica de pacientes.
BR0308556-2A 2002-03-21 2003-03-21 Tecnologia de otimização do segmento de sistema de serotonina e de catecolaminas BR0308556A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36698302P 2002-03-21 2002-03-21
PCT/US2003/008843 WO2003079886A2 (en) 2002-03-21 2003-03-21 Serotonin and catecholamine system segment optimization techonology

Publications (1)

Publication Number Publication Date
BR0308556A true BR0308556A (pt) 2005-05-03

Family

ID=28454829

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308556-2A BR0308556A (pt) 2002-03-21 2003-03-21 Tecnologia de otimização do segmento de sistema de serotonina e de catecolaminas

Country Status (7)

Country Link
US (3) US20030181509A1 (pt)
EP (1) EP1490073A4 (pt)
AU (1) AU2003222045A1 (pt)
BR (1) BR0308556A (pt)
CA (1) CA2479218A1 (pt)
MX (1) MXPA04009123A (pt)
WO (1) WO2003079886A2 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759437B2 (en) * 1999-10-04 2004-07-06 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity including cysteine
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
US20090311795A1 (en) * 2002-03-21 2009-12-17 Hinz Martin C Bilateral control of functions traditionally regulated by only serotonin or only dopamine
CA2479218A1 (en) * 2002-03-21 2003-10-02 Martin C. Hinz Serotonin and catecholamine system segment optimization technology
US20070293571A1 (en) * 2006-06-08 2007-12-20 Hinz Martin C Adminstration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes
AU2003903826A0 (en) * 2003-07-24 2003-08-07 University Of South Australia An ofdm receiver structure
WO2004075724A2 (en) * 2003-02-21 2004-09-10 Hinz Martin C Serotonin and catecholamine system segment optimization technology
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2004100929A1 (en) 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
JP4638685B2 (ja) * 2003-06-10 2011-02-23 ハイデルベルガー ドルツクマシーネン アクチエンゲゼルシヤフト オフセット印刷機による印刷の際に湿し水を調量する方法
WO2005025561A1 (en) * 2003-09-04 2005-03-24 Synergia Pharma, Inc. Compositions and methods for orthostatic intolerance
US20060030625A1 (en) * 2004-08-06 2006-02-09 Cheryle Ram Hart Dietary neurotransmitter precursors for balanced synthesis of neurotransmitters
US20070213370A1 (en) * 2005-11-18 2007-09-13 H. Lundbeck A/S 5-HTP Combination Therapy
DK1948155T3 (da) * 2006-06-28 2012-07-02 Chelsea Therapeutics Inc Farmaceutiske præparater omfattende droxidopa
ES2500053T3 (es) * 2007-03-09 2014-09-29 Chelsea Therapeutics, Inc. Composición farmacéutica que comprende droxidopa para el tratamiento de la fibromialgia
WO2008112773A2 (en) * 2007-03-12 2008-09-18 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension
WO2008137923A2 (en) * 2007-05-07 2008-11-13 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
WO2012004585A1 (en) * 2010-07-09 2012-01-12 Abdulla Badawy Ingestible formulation comprising glycomacropeptide and at least one of tryptophan, tyrosine and phenylalanine and uses thereof
JP2014503592A (ja) * 2011-01-26 2014-02-13 ニコ ワールドワイド，インコーポレイテッド 片頭痛の療法
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
EP2737809A1 (de) * 2012-12-03 2014-06-04 MüMed Aminosäurehaltiges Getränk, geeignet zur Verwendung in der Prophylaxe und Behandlung von psychischen Störungen
US11464756B1 (en) 2017-05-19 2022-10-11 Jerry Darm Mecuna pruriens, L-DOPA and 5-HTP based dietary supplements, pharmaceutical formulations and uses thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3097947A (en) * 1961-01-30 1963-07-16 Mend Johnson & Company Nutritional composition and process
US3795739A (en) * 1972-02-14 1974-03-05 Hoffmann La Roche Treatment of parkinson disease
US4237118A (en) * 1972-03-06 1980-12-02 Howard Alan N Dietary supplement and dietary methods employing said supplement for the treatment of obesity
US3810994A (en) * 1972-06-01 1974-05-14 Ethyl Corp Method and composition for treating obesity
US4397866A (en) * 1979-05-07 1983-08-09 Massachusetts Institute Of Technology Process for increasing glycine levels in the brain and spinal cord
US4377595A (en) * 1979-08-13 1983-03-22 Massachusetts Institute Of Technology Process for reducing depression
US4446138A (en) * 1982-02-10 1984-05-01 Pack Howard M Method and composition for reducing weight
JPS5925323A (ja) * 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
US4596807A (en) * 1985-03-26 1986-06-24 Serotonin Industries Of Charleston Method and compositions for controlling pain, depression and sedation
JPS61277618A (ja) * 1985-06-04 1986-12-08 Suntory Ltd 自閉症治療剤
US5189064A (en) * 1985-07-22 1993-02-23 Matrix Technologies, Inc. Treatment of cocaine addiction
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
US6048728A (en) * 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US5011608A (en) * 1988-11-18 1991-04-30 Dragana Damjanovic Biogenic amine assay using HPLC-ECD
US5084007A (en) * 1989-08-11 1992-01-28 Malin David H Method for chemical promotion of the effects of low current transcranial electrostimulation
US5019594A (en) * 1989-11-28 1991-05-28 Interneuron Pharmaceuticals, Inc. Method for decreasing appetite
CA2085230C (en) * 1990-06-13 2003-09-09 Albert H. Meier Process for activating reproduction of seasonal breeding animals by administering l-dihydroxyphenylalanine (l-dopa)
US5696128A (en) * 1994-07-07 1997-12-09 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method of regulating immune function
US5480657A (en) * 1993-10-27 1996-01-02 Allen; Ann De Wees T. Composition comprising caffeine chromium and fructose for weight control and use thereof
US5527788A (en) * 1994-01-18 1996-06-18 Louisiana State Univ. Medical Center Foundation Method and composition for treating obesity comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent
ES2177654T3 (es) * 1994-08-05 2002-12-16 Suntory Ltd Remedio contra la degeneracion espinocerebelosa.
US5502080A (en) * 1994-11-01 1996-03-26 Hitzig; Pietr Combined use of dopamine and serotonin agonists in the treatment of allergic disorders
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
WO1998001157A1 (en) * 1996-07-05 1998-01-15 The Wwk Trust Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin b12 and/or precursors or inducers of a neurotransmitter
US20010020007A1 (en) * 1996-08-26 2001-09-06 Oswald Wiss Vitamin preparations for reducing oxygen consumption during physical efforts
GB9617990D0 (en) * 1996-08-29 1996-10-09 Scotia Holdings Plc Treatment of pain
WO1998046248A1 (en) * 1997-04-14 1998-10-22 Anderson Byron E Method and material for inhibiting complement
US20010002269A1 (en) * 1997-05-06 2001-05-31 Zhao Iris Ginron Multi-phase food & beverage
US5795895A (en) * 1997-06-13 1998-08-18 Anchors; J. Michael Combination anorexiant drug therapy for obesity using phentermine and an SSRI drug
US5939076A (en) * 1997-11-12 1999-08-17 Allocca Techical, Inc. Composition and method for treating or alleviating migraine headaches
US6132724A (en) * 1998-04-29 2000-10-17 City Of Hope National Medical Center Allelic polygene diagnosis of reward deficiency syndrome and treatment
US20010008641A1 (en) * 1998-11-25 2001-07-19 R. Douglas Krotzer Nutritionally active composition for bodybuilding
DK1158973T3 (da) * 1999-02-24 2005-05-30 Univ Cincinnati Anvendelse af sulfamatderivater til behandling af impulskontrolafvigelser
US6261589B1 (en) * 1999-03-02 2001-07-17 Durk Pearson Dietary supplement nutrient soft drink composition with psychoactive effect
US6123724A (en) * 1999-04-14 2000-09-26 Denker; Stephen Heart assist method and apparatus employing magnetic repulsion force
US6207699B1 (en) * 1999-06-18 2001-03-27 Richard Brian Rothman Pharmaceutical combinations for treating obesity and food craving
US6955873B1 (en) * 2000-08-04 2005-10-18 Kenneth Blum Diagnosis and treatment system for reward deficiency syndrome (RDS) and related behaviors
DE19944788A1 (de) * 1999-09-18 2001-03-22 Utility Consult Hinzmann & Koe Verbrauchszähler für flüssige und gasförmige Medien
US6759437B2 (en) * 1999-10-04 2004-07-06 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity including cysteine
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
WO2001026642A2 (en) * 1999-10-08 2001-04-19 Joyce Corinne Bechthold Methods and compositions for treating neurobehavioral disorders
US20020147206A1 (en) * 2001-04-05 2002-10-10 Pfizer Inc. Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy
US20060014773A1 (en) * 2001-04-19 2006-01-19 Mccleary Edward L Mental agility lozenge, edible strip, food or drink
US6541043B2 (en) * 2001-08-28 2003-04-01 Dexgen Pharmaceuticals, Inc. Method and synergistic composition for treating attention deficit/hyperactivity disorder
US8142799B2 (en) * 2001-12-18 2012-03-27 Tamea Rae Sisco High potency clinical anti-craving treatment and method of use
CA2479218A1 (en) * 2002-03-21 2003-10-02 Martin C. Hinz Serotonin and catecholamine system segment optimization technology
US20060110325A1 (en) * 2003-02-21 2006-05-25 Hinz Martin C Serotonin and catecholamine segment optimization technology
AU2003228603A1 (en) * 2002-04-22 2003-11-10 Rtc Research And Development, Llc. Compositions and methods for promoting weight loss, thermogenesis, appetite suppression, lean muscle mass, increasing metabolism and boosting energy levels, and use as a dietary supplement in mammals
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US20040071681A1 (en) * 2002-10-10 2004-04-15 Lydia Muller Method and composition for reducing cravings for a craved substance
US20040116351A1 (en) * 2002-12-06 2004-06-17 Fast Balance, Inc. Method for enhancing the natural reward system for exercise
US20040151771A1 (en) * 2003-02-04 2004-08-05 Gin Jerry B. Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth
WO2004075724A2 (en) * 2003-02-21 2004-09-10 Hinz Martin C Serotonin and catecholamine system segment optimization technology
US20050233014A1 (en) * 2004-03-02 2005-10-20 Lee Steve S Methods for affecting homeostasis and metabolism in a mammalian body
US20060062859A1 (en) * 2004-08-05 2006-03-23 Kenneth Blum Composition and method to optimize and customize nutritional supplement formulations by measuring genetic and metabolomic contributing factors to disease diagnosis, stratification, prognosis, metabolism, and therapeutic outcomes

Also Published As

Publication number Publication date
EP1490073A2 (en) 2004-12-29
AU2003222045A8 (en) 2003-10-08
MXPA04009123A (es) 2005-09-08
AU2003222045A1 (en) 2003-10-08
US20080241278A1 (en) 2008-10-02
US20060178423A1 (en) 2006-08-10
EP1490073A4 (en) 2006-02-01
WO2003079886A3 (en) 2004-02-12
US20030181509A1 (en) 2003-09-25
WO2003079886A2 (en) 2003-10-02
CA2479218A1 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
BR0308556A (pt) Tecnologia de otimização do segmento de sistema de serotonina e de catecolaminas
ES2573733T3 (es) Tratamiento farmacológico del deterioro cognitivo
CY1116464T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
PE20040134A1 (es) Forma de dosificacion de una vez al dia de pramipexol
BR9909672A (pt) uso de um composto medicinal ativo no preparo de um medicamento para o tratamento de hipertensão
Tuite et al. Recent developments in the pharmacological treatment of Parkinson’s disease
ME02495B (me) Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda
Borah et al. Long-term L-DOPA treatment causes indiscriminate increase in dopamine levels at the cost of serotonin synthesis in discrete brain regions of rats
BR0314943A (pt) Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes
PT1885333E (pt) Formulação farmacêutica de apomorfina para administração bucal
WO2001054681A8 (en) Composition for treatment of stress
ATE493981T1 (de) Einmal tägliche dosierformen von trospium
DE60218193D1 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
BRPI0407619A (pt) tecnologia de otimização de segmento de sistema serotonina e catecolamina
EA200701017A1 (ru) Применение рибозы-цистеина для лечения гипоксии
Jankovic et al. Comparison of Sinemet CR4 and standard Sinemet: Double blind and long‐term open trial in parkinsonian patients with fluctuations
Zakaria et al. The potential role of melatonin on memory function: lessons from rodent studies
NO20062442L (no) Analgesiske suspensjoner md kontrollert frigivelse
BRPI0416882A (pt) composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
JP2008509170A (ja) カルビドパ／ベンセラジドを含むｌ−トリプトファンの新規製剤
US20090318555A1 (en) Treatment of Vertigo with Acetyl-L-Leucine
JPH0418034A (ja) 点眼組成物
Jonkers et al. MK801 influences L-DOPA-induced dopamine release in intact and hemi-parkinson rats
Claustrat et al. Melatonin in humans, neuroendocrinological and pharmacological aspects
Obering et al. Update on apomorphine for the rapid treatment of hypomobility (“off”) episodes in Parkinson's disease

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2156 DE 02/05/2012.